NATIONAL INSTITUTE FOR HEALTH CLINICAL EXCELLENCE

Health Technology Appraisal (MTA)

Drugs for the treatment of pulmonary arterial hypertension

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation					
Proposal:	Proposal made by:	Action taken:	Justification:		
		Removed/Added/Not included/Noted			
Some of the patient/carer groups listed (Action Heart and Heart UK) are primarily focused on hypertension, a different disease, and may have little to contribute on PAH	Encysive (UK) Ltd	Removed	This organisation's interests are not closely related to the appraisal topic and therefore they have been removed from the matrix of consultees and commentators.		
	representation of consultees and mary of comments, action tall proposal: Some of the patient/carer groups listed (Action Heart and Heart UK) are primarily focused on hypertension, a different disease, and may have little to contribute on	isional matrix of consultees and commentators sent for consultation and justification of action and proposal: Proposal: Proposal made by: Some of the patient/carer groups listed (Action Heart and Heart UK) are primarily focused on hypertension, a different disease, and may have little to contribute on	isional matrix of consultees and commentators sent for consultation mary of comments, action taken, and justification of action: Proposal: Proposal made by: Action taken: Removed/Added/Not included/Noted Some of the patient/carer groups listed (Action Heart and Heart UK) are primarily focused on hypertension, a different disease, and may have little to contribute on		

2.	Grown Up Congenital Heart Patients Association (GUCH) should be added to the list of	Encysive (UK) Ltd	Noted	Congenital Heart disease is not covered in the licence and therefore this organisation has not
	consultees			been included in the matrix of
				consultees and commentators.
3.	Beraprost is not used in the	Pulmonary Hypertension	Removed	This organisation does not have
	UK.	Association UK		marketing authorisation for their
				drug and therefore they have been
				removed from the matrix of
				consultees and commentators.
4.	National Consortium of	NICE Directorate	Added	This organisation has an area of
	Pulmonary Hypertension			interest closely related to this
	Directors			appraisal topic and meets the
				selection criteria to participate in
				this appraisal. National
				Consortium of Pulmonary
				Hypertension Directors has been
				added to the matrix of consultees
				and commentators under
				'professional groups'.

5.	The British Thoracic Society	NICE Directorate	Added	This organisation has an area of
				interest closely related to this
				appraisal topic and meets the
				selection criteria to participate in
				this appraisal. The British
				Thoracic Society has been added
				to the matrix of consultees and
				commentators under 'professional
				groups'.
6.	We can see no reason why	Pulmonary Hypertension	Removed	This organisation's interests are
	the following are being	Association UK		not closely related to the appraisal
	included, Action heart, The			topic and therefore they have
	British Cardiac Patient			been removed from the matrix of
	Association, Heart UK.			consultees and commentators.

7.	Are all of the experts from	Raynaud's & Scleroderma Association	Added	National Specialist
	the designated pulmonary			Commissioning Advisory Group
	hypertension centres in the			(NSCAG) have an area of interest
	UK also being consulted as			closely related to this appraisal
	they have data and			topic and meets the selection
	experience that would be			criteria to participate in this
	invaluable?			appraisal. NSCAG has been
				added to the matrix of consultees
				and commentators under
				ʻgeneral'.
				o o